The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). The needle is moving.
October 29, 2024 | 12:00 - 12:45 PM ET
Trinity explores some of the immediate challenges presented to New Products Planning (also known as Early Commercial Planning or New Product Commercialization) groups. Publication Access Form…
While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace. How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world? Publication Access Form…
Highlights from Trinity’s Recent Research Focused on Telehealth Since earlier this year when the COVID-19 virus outbreak began and quickly made its way around the globe, the way in which we operate has changed. Virtual communication for personal as well as business interactions is on the rise. Publication Access Form…
Highlights from Trinity’s Recent Research Focused on European HCP The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. As the EU5 countries comprise some of the most important pharmaceutical markets, and with Italy, Spain and France includes countries which have been impacted significantly from COVID-19, Trinity aimed to understand the impact on HCP engagement with Market Research. Publication access form…
Perspectives from 50+ Industry Forecasting Leaders, Highlights from Trinity’s Recent Research Focused on BioPharma Forecasting In a time of peak uncertainty, forecasters are being called on to answer some of the industry’s toughest questions surrounding the impact of COVID-19. Trinity is bringing together the latest data on challenges forecasters have been experiencing over the past few weeks. This research activity is a joint project of Trinity’s Forecasting Center of Excellence and its benchmarking division, TGaS Advisors. Publication Access Form…
The COVID-19 pandemic continues to have an unprecedented impact on our lives and is disrupting businesses as it spreads worldwide. The social distancing measures that are critically important to address the pandemic present new challenges with patient recruitment for clinical trials, market research, and drug launches. In this time of uncertainty, Trinity is assessing the impact on market research services including the ability of healthcare providers to participate in research. In its latest brief, “Impact of COVID-19 on Healthcare Market…
Trinity conducted a payer and employer advisory board to understand current perceptions of novel migraine therapies and potential strategies to improve access. Geographic Scope: Client Situation The client wanted to gather the payer and employer perspective on how the migraine landscape is evolving, and pressure test key strategic options as well as messages that they had developed. The employers included: Coca-Cola Company, Metro Nashville Public Schools, St. Louis Community College, and Vibra Healthcare. Trinity’s Solution Trinity conducted an unblinded advisory board with a diverse…
2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a product, we…
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success. In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…
Cell and Gene Therapy (CGT) is an exciting new frontier in the biopharmaceutical industry. The novelty of the technology and market introduces many complexities for companies commercializing CGTs. This white paper analyzes the challenges faced and outlines six key questions to consider for reducing complexity and supporting commercial success: Are we confident in the supply chain right up until administration of the treatment to the patient? Do we have the right pricing, reimbursement, and evidence model in place, not just…
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
